These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35116424)

  • 1. Preintervention MCP-1 serum levels as an early predictive marker of tumor response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    You R; Jiang H; Xu Q; Yin G
    Transl Cancer Res; 2021 Feb; 10(2):966-976. PubMed ID: 35116424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
    Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
    Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
    Guo M; Qi F; Rao Q; Sun J; Du X; Qi Z; Yang B; Xia J
    Front Immunol; 2021; 12():754961. PubMed ID: 34691076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating MiRNA-373 as a Predictor of Response to Super-selective Transarterial Chemoembolization Bridging Therapy in Hepatocellular Carcinoma Patients Awaiting Liver Transplantation.
    Tork ASE; Kamel AAF; Zaki MA; Abo El-Wafa RAH; El-Assar OS; Ibrahim Abdelkarem OA
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):291-299. PubMed ID: 36708579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of baseline Portal pressure (hepatic venous pressure gradient) and Indocyanine Green Clearance Test With Post-transarterial Chemoembolization Acute Hepatic Failure.
    Khisti R; Patidar Y; Garg L; Mukund A; Thomas SS; Sarin SK
    J Clin Exp Hepatol; 2019; 9(4):447-452. PubMed ID: 31516260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.
    Ishikawa K; Chiba T; Ooka Y; Suzuki E; Ogasawara S; Maeda T; Yokoyama M; Inoue M; Wakamatsu T; Kusakabe Y; Saito T; Tawada A; Arai M; Kanda T; Maruyama H; Imazeki F; Kato N
    Oncotarget; 2018 Apr; 9(30):21560-21568. PubMed ID: 29765560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nomogram Based on Preoperative Lipiodol Deposition after Sequential Retreatment with Transarterial Chemoembolization to Predict Prognoses for Intermediate-Stage Hepatocellular Carcinoma.
    Niu XK; He XF
    J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
    Guo J; Wang W; Zhang Y; Xu L; Kong J
    J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
    Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
    World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma.
    Tsai YJ; Hsu CY; Huang YH; Su CW; Lin HC; Lee RC; Chiang JH; Huo TI; Lee SD
    Hepatol Int; 2011 Dec; 5(4):975-84. PubMed ID: 21533669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying optimal candidates of transarterial chemoembolization (TACE)
    Zhao S; Dou W; Fan Q; Hu J; Li H; Zhang X; Zhang Q; Liu L
    Ann Transl Med; 2020 May; 8(9):587. PubMed ID: 32566614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction Model for Intermediate-Stage Hepatocellular Carcinoma Response to Transarterial Chemoembolization.
    Jia F; Wu B; Yan R; Li L; Wang K; Han D
    J Magn Reson Imaging; 2020 Dec; 52(6):1657-1667. PubMed ID: 32424881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
    J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic inflammatory response predicts poor prognoses in Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma with transarterial chemoembolization: a prospective study.
    Huang Z; Lu W; Yu N; Yang G; Xu H; Liu H
    Transl Cancer Res; 2019 Nov; 8(7):2552-2563. PubMed ID: 35117012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.